Volume 18, Number 3—March 2012
CME ACTIVITY - Research
Community-associated Clostridium difficile Infections, Monroe County, New York, USA
Table 6
Drug | NAP1/toxinotype III, μg/mL |
Other strains, μg/mL |
|||||
---|---|---|---|---|---|---|---|
MIC50 | MIC90 | Range | MIC50 | MIC90 | Range | ||
Clindamycin | <2 | >32 | <2 to>32 | <2 | >32 | <2 to >32 | |
Levofloxacin | >32 | >32 | <2 to >32 | 4 | >32 | <2 to >32 | |
Moxifloxacin | 16 | >32 | <2 to >32 | <2 | 32 | <2 to >32 | |
Metronizadole | 2 | 4 | <0.5 to 4 | <0.5 | 2 | <0.5 to 2 | |
Vancomycin | 1 | 2 | <0.5 to 2 | 1 | 2 | <0.5 to 2 |
*NAP, North American pulsed-field; CDI, Clostridium difficile infection. Clinical and Laboratory Standards Institute interpretive criteria (sensitive/ intermediate/resistant): clindamycin: <2/4/>8 μg/mL; levofloxacin: not available; moxifloxacin: <2/4/>8 μg/mL; metronidazole: <8/16/>32 μg/mL; vancomycin: not available.
Page created: February 23, 2012
Page updated: February 23, 2012
Page reviewed: February 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.